2025年8月1日，诺辉健康发布公告称已申请共同临时清盘人，距港交所18个月停牌红线仅剩月余，退市几成定局。公司停牌期间深陷财务造假风波，审计机构德勤拒绝签署财报，核心管理层集体离职，基金估值下调90%。尽管如此，其核心产品常卫清作为中国唯一获批的肠癌筛查产品，仍具稀缺性。国资此前曾参与其融资，目前是否介入重组尚无定论，但若介入将面临极高风险。诺辉能否续命，关键在于肠癌筛查注册证能否续期。
Source Link2025年8月1日，诺辉健康发布公告称已申请共同临时清盘人，距港交所18个月停牌红线仅剩月余，退市几成定局。公司停牌期间深陷财务造假风波，审计机构德勤拒绝签署财报，核心管理层集体离职，基金估值下调90%。尽管如此，其核心产品常卫清作为中国唯一获批的肠癌筛查产品，仍具稀缺性。国资此前曾参与其融资，目前是否介入重组尚无定论，但若介入将面临极高风险。诺辉能否续命，关键在于肠癌筛查注册证能否续期。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.